Treatment of Rheumatic Heart Disease with Mixed Mitral and Aortic Regurgitation

This protocol addresses the management of rheumatic heart disease presenting as mixed multivalve disease — specifically the combination of mitral regurgitation and aortic regurgitation occurring together.

Clinical scenario

The patient has rheumatic heart disease with concurrent mitral regurgitation and aortic regurgitation — a mixed multivalve pattern. This combination creates overlapping haemodynamic burdens that require a coordinated therapeutic approach.

Treatment approach (partial)

Medical therapy forms part of the management strategy in this setting, with an approach that may involve agents directed at afterload reduction, alongside other complementary pharmacological measures — the full structured regimen is detailed in the protocol.

Complete agent selection, sequencing, and clinical decision pathway available via the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1161/CIR.0000000000000921

In the most common scenario of multivalve disease with MR and AR, medical therapy with afterload reduction, diuretic agents, and possibly β-blockade may be complementary.

View source ↗